Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.

Werner PoeweFabrizio StocchiDavid ArkadirGeorg EbersbachAaron L EllenbogenNir GiladiStuart H IsaacsonKarl KieburtzPeter LeWittC Warren OlanowTanya SimuniAstrid ThomasAbraham ZlotogorskiLiat AdarRyan CaseSheila OrenShir Fuchs OrenbachOlivia RosenfeldNissim SassonTami YardeniAlberto J Espaynull null

Published in: Movement disorders : official journal of the Movement Disorder Society (2021)

Subcutaneous levodopa/carbidopa continuous infusion with ND0612 is generally safe, with typical infusion site reactions for SC delivery as the main adverse event. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

low dose
open label
parkinson disease
deep brain stimulation
clinical trial
electronic health record
big data
squamous cell carcinoma
randomized controlled trial
phase iii
systematic review
locally advanced